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1. Introduction 
Lecithin-cholesterol acyl transferase is active in 
the production of cholesterol esters and lysolecithin 
from the free cholesterol and lecithin moieties of the 
mammalian plasma lipoproteins, and is the major 
source of human plasma cholesterol esters [ 1, 21. In 
the present research, this enzyme has been purified 
2500-fold from human plasma. The purified enzyme 
is active only against the HDLa and VHDL classes of 
plasma lipoproteins. It has a half life of 3 hr at 4”. 
The protein moiety of these classes is required for 
the significant esterification of cholesterol in sonically 
dispersed lipid emulsions. 
2. Materials and methods 
LCAT activity was assayed as the synthesis of 
labeled cholesterol esters in whole plasma or isolated 
lipoproteins labeled by incubation with albumin-bound 
3H-cholesterol [3] . The cholesterol was purified in 
the laboratory by thin-layer chromatography to 
remove radioactivity in the cholesterol ester band. 
Either native plasma or lipoproteins, or samples 
heated at 58” for 30 min to inactivate endogenous 
LCAT activity [3] , was used in the assay medium. 
Abbreviations: 
VLDL : very low density lipoprotein d < 1.006 
LDL : low density lipoprotein 1.019 < d < 1.063 
HDLl : high density lipoprotein 1.063 < d < 1.12 
HDL3 : high density lipoprotein 1.12 < d < 1.21 
VHDL : very high density lipoprotein 1.21 < d < 1.25 
LCAT : lecithin-cholesterol acyl transferase 
North-Holland Publishing Company - Amsterdam 
Each was labeled to a specific activity in unesterified 
cholesterol of 0.0 1 /.&i/pg. Following incubation 
with the enzyme samples (0.20 ml assay), total lipid 
was extracted with 5 ml chloroform-methanol 
(1: 1 v/v). Aliquots were developed on silica gel G 
plates in hexane-diethyl ether-acetic acid (83: 16: 1 
v/v). The cholesterol ester bands visualized with 
iodine vapour were scraped off and radioactivity 
determined in glass vials containing 10 ml of scintil- 
lation fluid (100 g naphthalene, 10 g POP, 0.5 g 
POPOP/liter toluene) in a Series 3000 Packard liquid 
scintillation spectrometer with automatic standard. 
Lipoprotein fractions (VLDL, LDL, HDLs , HDL3, 
VHDL) were isolated by ultracentrifugal flotation in 
KBr-NaCI solutions [4] Delipidation of HDLz, 
HDL3 and VHDL was carried out with ethanol-ether 
(2: 1 v/v) and sonicated dispersions of the extracted 
lipoprotein lipids were prepared in 0.145 M NaCl [5] . 
Protein was measured by the ninhydrin method [6] 
after hydrolysis in 6 N HCl at 110” for 21 hr, and 
also according to Lowry [7]. Phospholipids and 
cholesterol in lipoprotein lipids were determined 
according to the regular laboratory procedures [ 8,9] . 
Recrystallized bovine serum albumin was obtained 
from Armour, Chicago. Dcuterium oxide (99.7% 
DzO) and hydroxyl apatite (Biogel HT) were pur- 
chased from Biorad, Richmond, California, and 
caesium chloride (99+% CsCl) from Matheson, Ohio. 
3. Results 
LCAT activity was purified from the fresh plasma 
of healthy non-fasting male donors. (Fasting plasma 
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preincubated with l/40 vol. intralipid 10% triglyceride 
emulsion (Vitrum, Sweden) was also successfully used 
in preliminary experiments). All manipulations with 
enzyme fractions were carried out at 4-5” except 
where stated. 100 ml portions of plasma were ob- 
tained from blood collected into l/20 vol. 0.2 M 
sodium citrate after centrifugation for 20 min at 
2,000 g. These were brought to 66% saturation of 
(NH4)zS04 by addition of the solid salt. After 
standing in ice for 60 min, the precipitate was centri- 
fuged down at 20,000 rpm for 20 min and then dis- 
persed in 25 ml of DzO-0.005 M EDTA, pH 7.2 
(‘DzO-EDTA’). After stirring for 60 min, the un- 
dissolved residue was removed by centrifugation as 
before. The supernatant contained the bulk of LCAT 
activity (table 1). Solid CsCl was added to 14.5% w/v 
and 3 ml samples were layered under the same volume 
of DaO-EDTA-14.5% CsCl (d = 1.21) in the cellulose 
nitrate tubes of a Spinco 40.3 rotor. Centrifugation 
was for 36 hr at 40,000 rpm at 5-6” in a Type L2-65 
ultracentrifuge. After the run, the tubes were sliced 
(Beckman tube slicer) to isolate the clear intermediate 
zone between the supernatant orange band containing 
the bulk of the lipoprotein, and the yellow infranatant 
of plasma albumin. The active fraction was then 
mixed with 0.1 g CsCl/ml and layered as before under 
an equal vol. of D,O-EDTA-18% CsCl w/v (d = 1.25). 
Centrifugation was for 36 hr at 35,000 rpm. The clear 
intermediate zone was again removed by slicing and 
contained the bulk of LCAT activity purified about 
350-fold from the plasma in 30-35% yield (table 1). 
Addition of 2-mercaptoethanol(1 mM final concentra- 
tion) during the centrifugation procedure did not in- 
crease purification or recovery. Further purification 
was carried out by chromatography on hydroxyl 
apatite in 0.02 M potassium phosphate buffer con- 
taining 27% w/v NaBr, pH 7.2. After equilibration of 
0.9 X 5.0 cm columns with this buffer, in which 
medium dissociation of enzyme substrate complex in 
the LCAT system is maximal [lo] , 1 ml of the active 
fraction from the preceding step was made 0.02 M in 
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Fig. 1. LCAT activity against human plasma and lipoprotein 
fractions. Assays contained 0.02 ml lipoprotein solution (100 
pg free cholesterol/ml, 0.01 Ki/H) + 0.02 ml 10% bovine 
serum albumin in 0.145 M NaCl, pH 7.4 + 0.155 ml 0.145 M 
NaCl + 0.005 ml purified LCAT solution or potassium phos- 
phate-NaBr buffer. Control tubes without added LCAT were 
assayed with each lipoprotein fraction. Incubation was for 3 
hr at 37”, after preincubation (without added LCAT) for 30 
min at 37”. 
Table 1 
Purification of lecithin-cholesterol acyl transferase. 
-- --- -- 
Vol. 
Total Total 
Fraction 
(ml) 
activity protein Activity/mg protein Yield Purification 
(units*) (mg**) 
(fold) 
~- 
Original plasma 100 6600 6230 1.06 1 .oo 1 .oo 
Soluble fraction 
from (NH4)aS04 59 5185 3735 1.38 0.80 1.3 
Ultracentrifuge fraction 12.5 2113 5.5 384.2 0.32 362 
Hydroxyl apatite eluate 16.0 1183 0.40 2956 0.18 2788 
~-- ~-~_--_-_-_ ~____ 
* 1 unit of enzyme catalyzed the esterification of 1 nmole unesterified cholesterol/hr from whole native plasma at 37” and pH 7.4. 
** By the ninhydrin method [6]. 
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phosphate buffer and 27% w/v in NaBr and passed 
into the column. The flow rate was 1 ml/hr, and 1 ml 
fractions were collected. The column was washed with 
5 ~01s. of potassium phosphate-NaBr buffer, then 
with 5 ~01s. of the same buffer made 0.05 M in sodium 
citrate. 25-50% of added enzyme activity passed 
directly through the column. This was inactive against 
extracted lipoprotein lipids in the absence of the lipo- 
protein protein moiety, as described below. The re- 
mainder of applied activity was eluted in the citrate 
fraction. This latter fraction did not show a require- 
ment for lipoprotein protein, as shown by activity 
against lipoprotein lipids alone. A final purification 
of about 2500-fold in lo-15% yield was obtained 
(table 1) in terms of protein as measured by the nin- 
hydrin reaction after acid hydrolysis [6] Protein 
determination by the method of Lowry [7] gave 
calculated purifications of up to lO,OOO-fold presum- 
ably due to a low content of tyrosine in the purified 
LCAT fraction. The purified enzyme had a half-life 
of activity of 3 hr at 4’. The activity of the purified 
LCAT fraction against the lipoproteins of the plasma 
was determined. As shown in fig. 1, only HDLs and 
VHDL were effective substrates for this enzyme. Small 
amounts of cholesterol esterification (O-S% the rate 
of HDLs, 4 experiments) were usually seen in VLDL, 
LDL and HDLs. In view of the routine use of whole 
heated human plasma suggested for the assay of LCAT 
[3], it was of interest to determine whether heating 
affected the rates of esterification obtained. A signi- 
ficantly reduced rate of esterification was found in 
whole plasma, HDLs and VHDL (fig. 1). 
The delipidated proteins of HDLs and VHDL were 
cofactors for the effective esterification of the choles- 
terol fraction of sonicated emulsions of HDLz, HDLs 
or VHDL lipids (fig. 2). Under the given assay condi- 
tions, maximal activity was obtained at 50 pg lipo- 
protein protein/ml assay medium, representing a 
protein:phospholipid ratio of 1 .O:OS. Under the same 
conditions, delipidated HDLz, in assays containing 
the lipids of HDLs, HDLs or VHDL, permitted a 
lower, but significant rate of esterification of 
cholesterol (20-35% HDLs, 4 experiments). Signifi- 
cant cofactor activity was always present in the d > 1.25 
infranate, even after extensive centrifugation to 
remove VHDL (for 48 hr at 40,000 rpm in the 40.3 
rotor of the ultracentrifuge). These cofactor activities 
were obtained whether the 3H-cholesterol abel was 
*n=ym*‘l: 
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Fig. 2. LCAT activity against HDLs lipids in the presence of 
delipidated lipoprotein protein. Assays contained 0.02 ml 
sonicated HDLs lipids (100 pg free cholesterol/ml, 0.01 
Ki/rg) + 0.02 ml 10% bovine serum albumin in 0.145 M 
NaCl, pH 7.4 + 0.05 ml of delipidated lipoprotein protein 
solution (0.145 M NaCl, 0.005 M NH40H-NH&l, pH 8.1) + 
0.105 ml 0.145 M NaCl + 0.005 ml purified LCAT or buffer 
solution. Assay conditions were as in fig. 1. 
added by equilibration with cholesterol-bound albumin, 
or incorporated directly into the extracted lipoprotein 
lipid before its dispersion sonication. 
4. Discussion 
The foregoing experiments demonstrate a cofactor 
protein requirement for the esterification of cholesterol 
by purified lecithin-cholesterol acyl transferase, and 
also reveal an unexpected specificity in its interaction 
with the plasma lipoprotein classes. The preparation 
of enzyme by flotation with endogeneous lipid allows 
a purification similar to that recently obtained by use 
if added lecithin micelles [ 1 l] . However, in the 
present research, no protection of activity by 
2-mercaptoethanol has been obtained. Possibly the 
effect described represents a stabilization of the 
added lipid against oxidation. The fraction isolated 
by either method has no protein cofactor requirement 
for the esterification of cholesterol. The further 
purification obtained in the present research by 
hydroxyl apatite chromatography of the active frac- 
tion, has made use of the observations of Akanuma 
and Glomset [lo] that LCAT is passed through such 
columns under conditions of low phosphate concen- 
tration when much other plasma protein is retained. 
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The final product shows an absolute requirement for 
lipoprotein protein cofactor (fig. 2), similar to that 
required for the triglyceride hydrolase activity of 
purified lipoprotein lipase [ 121. No significant differ- 
ences were found in the activities of HDLa and VHDL 
as substrates and cofactors of LCAT activity (figs. 1 
and 2). Native HDL was almost inactive (fig. 1) al- 
though the delipidated protein moiety, in the presence 
of its own or HDLa lipids, showed a significant activity 
(fig. 2). It appears likely that the lack of esterification 
of HDLz cholesterol by LCAT represents not sub- 
stantial lack of a specific protein cofactor, but is 
rather, at least in part, a feature of the native lipo- 
protein structure. The quite different activity of native 
HDLz and HDLa in cholesterol esterification, suggests 
that these may represent separate intermediates in the 
metabolism of plasma lipoprotein lipids. 
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